Equities

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)57.03
  • Today's Change0.000 / 0.00%
  • Shares traded681.38k
  • 1 Year change+90.48%
  • Beta0.6037
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

  • Revenue in USD (TTM)1.04m
  • Net income in USD-277.91m
  • Incorporated2008
  • Employees290.00
  • Location
    Crinetics Pharmaceuticals Inc10222 Barnes Canyon Rd Bldg 2SAN DIEGO 92121-2711United StatesUSA
  • Phone+1 (858) 450-6464
  • Fax+1 (302) 636-5454
  • Websitehttps://www.crinetics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rhythm Pharmaceuticals Inc112.53m-261.57m3.63bn226.00--323.37--32.24-4.31-4.311.862.490.31361.186.65497,920.30-72.15-47.21-90.85-52.8488.61---230.11-681.383.34--0.417--227.56---1.97---42.10--
Alvotech SA393.92m-441.45m3.75bn999.00------9.52-1.90-1.901.56-1.290.35951.564.24394,313.30-40.28---47.87--59.03---112.07--1.92-0.05191.41--9.84---7.43------
Immunovant Inc0.00-323.01m3.90bn207.00--8.66-----2.21-2.210.003.060.00----0.00-79.97---92.17--------------0.00-------22.93------
Ultragenyx Pharmaceutical Inc522.75m-558.99m4.25bn1.28k--12.25--8.13-6.46-6.466.023.760.37661.916.06409,674.80-40.27-33.35-50.12-38.3086.2593.13-106.93-154.712.65--0.00--19.5253.1814.25--62.91--
Biohaven Ltd0.00-804.34m4.45bn239.00--13.57-----9.35-9.350.003.330.00----0.00-180.09---236.99--------------0.00------28.43------
Alkermes Plc1.51bn502.58m4.48bn2.10k9.393.478.262.982.951.968.837.990.67881.324.24716,724.3022.671.3428.901.7483.1783.3233.392.123.03--0.18270.0049.618.741,665.99---7.10--
Arcellx Inc155.82m-40.42m4.72bn130.00--9.75--30.27-0.7196-0.71962.988.950.226----1,198,600.00-5.86-38.82-7.56-45.41-----25.94-339.38----0.022------62.53--113.86--
Crinetics Pharmaceuticals Inc1.04m-277.91m5.09bn290.00--5.53--4,902.86-3.72-3.720.013910.300.0013--0.12223,582.76-34.61-42.53-36.80-45.36-----26,298.27-5,446.39----0.00---15.2810.57-30.88--34.65--
Krystal Biotech Inc241.52m52.37m5.24bn229.00103.145.9288.2421.711.771.778.2130.800.27251.514.531,054,664.005.91-11.506.33-12.0192.55--21.68-492.857.76--0.00------107.81--39.49--
Ionis Pharmaceuticals Inc803.07m-358.81m5.36bn927.00--8.09--6.67-2.45-2.455.504.200.2670.386410.02866,306.40-11.93-6.30-13.52-7.4498.7098.75-44.68-21.238.82--0.6587--34.105.60-35.80--11.83--
TG Therapeutics Inc264.79m-14.36m5.38bn319.00--28.01--20.31-0.1067-0.10671.741.230.57750.52343.421,002,992.00-3.13-62.87-3.91-80.0688.32---5.42-405.033.910.20970.5596--8,290.02333.86106.39------
Cytokinetics, Inc.3.22m-576.40m5.63bn423.00------1,747.67-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Viking Therapeutics Inc0.00-99.15m5.75bn33.00--6.31-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Nuvalent Inc0.00-224.29m6.05bn127.00--5.87-----3.48-3.480.0015.810.00----0.00-27.79---29.25--------------0.00-------54.20------
Blueprint Medicines Corp434.41m-128.05m6.14bn638.00--19.58--14.13-2.11-2.116.924.930.37690.89548.11663,227.50-11.11-29.92-13.84-34.0697.01---29.48-116.653.27-10.800.5525--22.2241.149.06--4.85--
Data as of Nov 21 2024. Currency figures normalised to Crinetics Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

47.86%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20246.06m6.73%
Driehaus Capital Management LLCas of 30 Sep 20245.89m6.54%
BlackRock Fund Advisorsas of 30 Sep 20245.81m6.45%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 20244.86m5.39%
EcoR1 Capital, LLCas of 30 Sep 20244.29m4.76%
Wellington Management Co. LLPas of 30 Sep 20244.16m4.63%
Fidelity Management & Research Co. LLCas of 30 Sep 20243.88m4.31%
SSgA Funds Management, Inc.as of 30 Sep 20242.84m3.15%
Jennison Associates LLCas of 30 Sep 20242.79m3.10%
Paradigm BioCapital Advisors LPas of 30 Sep 20242.52m2.80%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.